OTCMKTS:ATBPF

Antibe Therapeutics (ATBPF) Stock Forecast, Price & News

$0.36

0.00 (0.00%)

(As of 09/29/2023 ET)

Compare

Today's Range: $0.36
▼
$0.36
50-Day Range: $0.34
▼
$0.43
52-Week Range: $0.28
▼
$0.53

Volume: N/A
Average Volume: 10,688 shs
Market Capitalization: $18.86 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Analyst Ratings Chart Competitors Earnings Headlines Short Interest

About Antibe Therapeutics (OTCMKTS:ATBPF) Stock

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

ATBPF Price History

30 days | 90 days | 365 days | Advanced Chart

ATBPF Stock News Headlines

September 8, 2023 | finance.yahoo.com

Antibe Announces Results of 2023 Annual Meeting

August 14, 2023 | finance.yahoo.com

Antibe Reports Q1 2024 Interim Financial and Operating Results

October 2, 2023 | Behind the Markets (Ad)

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"

The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>

June 29, 2023 | finance.yahoo.com

Antibe Reports 2023 Year-End Results and Business Highlights

April 12, 2023 | theglobeandmail.com

Closing Bell: Antibe Therapeutics Inc down on Tuesday (ATE)

April 6, 2023 | theglobeandmail.com

Closing Bell: Antibe Therapeutics Inc up on Wednesday (ATE)

March 12, 2023 | finance.yahoo.com

Antibe Therapeutics Inc. (ATBPF)

February 16, 2023 | markets.businessinsider.com

Maxim Group Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)

October 2, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.

February 15, 2023 | markets.businessinsider.com

Echelon Wealth Partners Reaffirms Their Buy Rating on Antibe Therapeutics (ATBPF)

February 9, 2023 | theglobeandmail.com

Antibe Therapeutics: Top 25 Undervalued Dividend Stocks on TSX (ATE)

February 7, 2023 | theglobeandmail.com

Antibe Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (ATE)

November 22, 2022 | finance.yahoo.com

ATBPF: On Track to Initiate Phase 2 Trial for Otenaproxesul in 1H23…

October 12, 2022 | finance.yahoo.com

Antibe Provides Development Update for Otenaproxesul

September 9, 2022 | finance.yahoo.com

Antibe Announces Results of 2022 Annual Meeting

September 6, 2022 | finance.yahoo.com

Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022

July 8, 2022 | finance.yahoo.com

ATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22…

July 2, 2022 | finance.yahoo.com

Will Antibe Therapeutics (TSE:ATE) Spend Its Cash Wisely?

June 30, 2022 | finance.yahoo.com

Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights

April 25, 2022 | nz.finance.yahoo.com

Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

February 16, 2022 | seekingalpha.com

Antibe Therapeutics GAAP EPS of -$0.09

February 14, 2022 | finance.yahoo.com

Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results

January 28, 2022 | nasdaq.com

ATBPF Real-Time Quotes

December 1, 2021 | finance.yahoo.com

ATE.TO: Development Plan in Place for Otenaproxesul in Acute Pain…

October 14, 2021 | msn.com

BRIEF-Antibe Therapeutics Provides Update On Otenaproxesul And Expanded Drug Pipeline

October 14, 2021 | finance.yahoo.com

Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline

August 19, 2021 | finance.yahoo.com

Antibe Therapeutics Announces Results of 2021 Annual Meeting

See More Headlines

Receive ATBPF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATBPF Company Calendar

Last Earnings: 8/14/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 3/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ATBPF
CUSIP: N/A
CIK: N/A
Web: www.antibethera.com
Phone: (416) 922-3460
Fax: N/A
Employees: 11
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,730,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.80%
Return on Assets: -27.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.57
Quick Ratio: 8.57

Sales & Book Value

Annual Sales: $7.67 million
Price / Sales: 2.46
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.58 per share
Price / Book: 0.62

Miscellaneous

Outstanding Shares: 52,640,000
Free Float: 47,900,000
Market Cap: $18.86 million
Optionable: Not Optionable
Beta: 0.36

The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Daniel Marcel Legault J.D. (Age 65)
L.L.B., Pres, CEO, Sec. & Director
Comp: $549.34k

Mr. Alain Wilson M.B.A.
MBA, Chief Financial Officer

Mr. Scott Curtis C.F.A.
M.Eng, Chief Operating Officer

Dr. David James Vaughan Ph.D. (Age 73)
Chief Devel. Officer
Comp: $299.94k

Dr. Joseph Stauffer D.O. (Age 57)
M.B.A., Chief Medical Officer
Comp: $818.8k

Dr. Ana Stegic
Exec. Director of Clinical Operations

Ms. Christina Cameron B.B.A.
VP of Investor Relations

Mr. Philip Stern
VP of Communications

Key Competitors

View All Competitors

ATBPF Stock - Frequently Asked Questions

Should I buy or sell Antibe Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATBPF shares.
View ATBPF analyst ratings or view top-rated stocks.
How have ATBPF shares performed in 2023?: Antibe Therapeutics' stock was trading at $0.3230 at the beginning of the year. Since then, ATBPF stock has increased by 10.9% and is now trading at $0.3583.
View the best growth stocks for 2023 here.
Are investors shorting Antibe Therapeutics?: Antibe Therapeutics saw a decline in short interest in September. As of September 15th, there was short interest totaling 6,900 shares, a decline of 76.4% from the August 31st total of 29,200 shares. Based on an average daily volume of 27,000 shares, the days-to-cover ratio is currently 0.3 days.
View Antibe Therapeutics' Short Interest.
When is Antibe Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ATBPF earnings forecast.

How were Antibe Therapeutics' earnings last quarter?: Antibe Therapeutics Inc. (OTCMKTS:ATBPF) posted its quarterly earnings data on Monday, August, 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01.
What is Antibe Therapeutics' stock symbol?: Antibe Therapeutics trades on the OTCMKTS under the ticker symbol "ATBPF."
How do I buy shares of Antibe Therapeutics?: Shares of ATBPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Antibe Therapeutics' stock price today?: One share of ATBPF stock can currently be purchased for approximately $0.36.
How much money does Antibe Therapeutics make?: Antibe Therapeutics (OTCMKTS:ATBPF) has a market capitalization of $18.86 million and generates $7.67 million in revenue each year. The company earns $-14,730,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.
How can I contact Antibe Therapeutics?: Antibe Therapeutics' mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The official website for the company is www.antibethera.com. The company can be reached via phone at (416) 922-3460 or via email at christina@antibethera.com.

This page (OTCMKTS:ATBPF) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial